Jun. 3 at 10:37 PM
$RIGL I see a lot of (what in my opinion are) low estimates on this board in terms of buyout prices. It is understandable, but patience is the enemy for retail investors - people are tired. In my view, Veppanu is going to supercharge sales. Rigel has been brilliant in terms of bringing in drugs that market themselves as they are aimed at genetic mutations. Once the mutations are mapped the physician knows what to prescribe - and Veppanu is going to be exciting. It may take a little while to ramp but I don't think long. The huge home run driver, in my mind, is that Rigel wants to become a post-venetoclax and/or combo w/venetoclax company. Rezlidhia is already being studied this way by MD Anderson and R289 sounds extremely promising and fits perfectly into the LR/MDS/ AML space (and other indications as well). Can't wait for the ASH data, and if it pans in treatment naive patients in 2027, the price tag goes very high. We can't give this one away for peanuts.
